ND 2001

Drug Profile

ND 2001

Latest Information Update: 20 Jun 2001

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Class Antineoplastics; Small molecules; Sugar acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer metastases

Most Recent Events

  • 20 Jun 2001 No-Development-Reported for Cancer metastases in Japan (Unknown route)
  • 24 Nov 1998 A preclinical study has been added to the pharmacodynamics section
  • 02 Jan 1998 Preclinical development for Cancer metastases in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top